Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02908516 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy of Oral TXA in Reducing Blood Loss and Transfusion in Hip Fractures
A Phase 4 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT02908516 is a Phase 4 study that was terminated before completion, run by Yale University. The registered enrollment target is 6 participants.
The verdict
NCT02908516, a Phase 4 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the safety and efficacy of Tranexamic acid (TXA) in reducing blood loss and transfusion requirements for patients with osteoporotic hip fractures. In addition to assessing blood loss in these patients, complications associated with TXA use would be characterized including systemic (pulmonary embolism, deep venous thrombosis, myocardial infarction, stroke) and surgical site (hematoma, infection) events, need for re-hospitalization or re-operation and 30 day mortality.
Interventions
- DRUG Placebo
- DRUG Tranexamic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-09-18 |
| Est. Completion | 2017-12-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02908516
The ClinicalTrials.gov registry entry for NCT02908516 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02908516 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02908516 about?
NCT02908516 is a clinical study titled "Safety and Efficacy of Oral TXA in Reducing Blood Loss and Transfusion in Hip Fractures". The primary objective of this study is to assess the safety and efficacy of Tranexamic acid (TXA) in reducing blood loss and transfusion requirements for patients with osteoporotic hip fractures. In addition to assessing blood loss in these patients, complications associated with TXA use would be ch...
What is the current status of trial NCT02908516?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2017-09-18. Estimated completion is 2017-12-15.
What interventions are being tested in trial NCT02908516?
The interventions under investigation include: Placebo (DRUG), Tranexamic Acid (DRUG).
Who is sponsoring clinical trial NCT02908516?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.